6 резултати
FIELD OF INVENTION
This invention relates to a novel treatment for treating cancers or multidrug-resistant cancers, in particular, a novel treatment involving the use of an AMPK activator, hernandezine or thalidezine.
BACKGROUND OF INVENTION
AMP activated protein kinase (AMPK), which maintains
FIELD OF INVENTION
This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions.
BACKGROUND OF INVENTION
Autophagy is a cellular
FIELD OF INVENTION
This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions.
BACKGROUND OF INVENTION
Autophagy is a cellular
FIELD OF INVENTION
This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions.
BACKGROUND OF INVENTION
Autophagy is a cellular
FIELD OF INVENTION
This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions.
BACKGROUND OF INVENTION
Autophagy is a cellular
FIELD OF INVENTION
This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions.
BACKGROUND OF INVENTION
Autophagy is a cellular